Acute Lymphocytic Leukemia

Watchlist

(log in to enable)

Retrieved

2023-08-16

Source

Mayo_clinic

Trials

—

Genes

NOTCH1, IKZF1, CDKN2A, SH2B3, FBXW7, BLM, LIG4, KMT2A, PTEN, LMO2, EZH2, NOTCH3, FLT3, ETV6, NBN, NUDT15, CD6, TRBV20OR9-2, CD19, MS4A1, TCF3, CD33, TAL1, CD22, H3P10, SPG7, GNB1, KRT20, NR3C1, CRLF2

NOTCH1, IKZF1, CDKN2A, SH2B3, FBXW7, BLM, LIG4, KMT2A, PTEN, LMO2, EZH2, NOTCH3, FLT3, ETV6, NBN, NUDT15, CD6, TRBV20OR9-2, CD19, MS4A1, TCF3, CD33, TAL1, CD22, H3P10, SPG7, GNB1, KRT20, NR3C1, CRLF2, CSF2, RUNX1, PTPN11, GSTP1, GSTT1, CASR, PSMB6, PRKAR1A, ASRGL1, CD34, TNF, TRG, CD38, CSF3, MRPL28, CXADR, TBC1D9, CYP1A1, TRIM13, DHFR, NQO1, NR1I3, ATN1, ABCG2, HPGDS, CEBPE, DLL1, KIT, CNTNAP1, CDR3, CDKN2B, NXT1, CXCR4, YY1, ERG, EVPL, TYMS, TPMT, TP53, PIK3CG, FANCB, TRGC1, PMS2, GSTM1, PIK3CD, IL7, OPN1SW, BCL2, GSTK1, ASPG, MTTP, MTHFR, IGH, MPO, ARR3, MME, AFF1, MYC, ANPEP, MDM2, TARP, CXADRP1, ITPA, JAK1, ALL1, JAK2, ABL1, H3P9, BCR, ABCC1, SUB1, NRAS, HTC2, ABCB1, PIK3CA, PIK3CB, TMEM132D, ARID5B, PBX1, SLCO6A1, PAX5, HLF, IL3, FAS, IL2, GGH, AKT1, IL7R, WT1, CD44, NT5C2, CCND1, IFNG, RFC1, IL6, VEGFA, ASNS, ARHGAP24, CDK2, SLC19A1, IL3RA, CREBBP, CYP3A5, CCN2, IL10, CYP3A4, WLS, IL18R1, EBI3, IFNA1, CDKN1C, TP73, IFNA13, ZNF384, BCL6, FHIT, SAI1, S100A4, ATM, MSH3, MLLT10, HLA-DRB1, AICDA, MEF2D, RAG1, STAT5A, HRX, CTNNB1, STAT5B, MTX1, JAK3, GATA3, MTRR, ATG5, GEM, MLLT1, NRP1, IL15, PICALM, TLX1, HOXA9, EBF1, MCL1, KIR3DL1, ROPN1L, RBM45, ASPM, C3, CES1, ASPA, ASIP, MARCKSL1, CRYZ, DUX4, A1CF, MIR196B, LINC02605, MTOR, BTG1, HERPUD1, CALCA, HLA-A, BLNK, CD86, NUP214, CASP3, CDK4, RUNX1T1, SCT, SNAP25, EP300, ROR1, LEF1, MIR155, IGF2BP1, BCL2L11, MERTK, CYP2D6, IL2RA, MSH2, MTAP, MDM4, CCR7, MTR, KRAS, FOXO3, MLLT3, TGFB1, TG, SOAT1, TNFRSF9, CD40, FGFR1, FUT4, ADA, SPP1, TRD, CEP72, CD27, LRP1, FPGS, IDH1, CXCL12, BCRP2, NCAM1, HPRT1, IDH2, PDGFRB, P2RY8, HOXA@, BAX, TLX3, CALM1, GLS, CALM2, CALM3, PML, HLA-B, COL18A1, MIR146A, PTPRC, RB1, CSF1R, NAT2, ABCC3, CD52, CDKN1A, EPOR, CDKN1B, MVP, SNAP91, CYP2E1, FOXP1, PROM1, CDK6, EIF4E, HFE, PRKAA2, TRDJ1, NME1, MSI2, NPM1, PTPN6, TNFRSF13C, DERL1, SERPINE1, TSLP, CASP8, HDAC9, MAPK3, HDAC1, F2, ADIPOQ, HSP90AA1, PIP4K2A, HLA-DPB1, PRKAB1, PRKAA1, TCF7L1, BMI1, RALGAPB, A2ML1, KDR, AFF3, LAMC2, RPSA, LEP, CTCF, ISG20, BCRP3, COX8A, MEIS1, IL18, EIF2AK4, MLH1, MIR34B, MIR221, APAF1, CYP2B6, BIRC5, EFS, IL1B, SIRT1, MIRLET7B, IGFBP7, LINC01194, DCK, IGF1R, RMDN2, MYB, ZNF521, PTPRA, B3GAT1, PAG1, FANCL, WEE1, NLRP2, RTEL1, CD79A, CDKN2C, CD40LG, SHMT1, WNT5A, TRDC, ERCC2, ZAP70, GATA1, OPN1LW, ACKR3, CD7, PCBP4, RARA, TRDD3, SYK, FLT1, TAC1, PRAME, MIR203A, MIR181A2, SMUG1, SYNE1, ZNF197, MIR150, UHRF1, XPO1, UGT1A1, LAMTOR1, PPP1R13B, MMP9, TCF7L2, NSD2, MIR142, ABCC4, MIR126, TNFSF10, CIB1, MIR223, TERT, NUDC, KRT7, IGK, VDR, UBE2I, RMDN1, LCK, VWF, WT1-AS, H3P12, MIR1290, CXCR6, IL24, LMNA, LMO1, RASSF10, ATRAID, LPA, PTP4A3, SCLY, MDK, PACSIN2, MIR335, TLR4, MAP3K7, CD99, TFRC, RMDN3, AUTS2, LRPPRC, PGF, ABCB4, PHF2, PMEL, AFF4, GLS2, SET, DHX32, NR0B2, LPAR2, HAP1, CCNA1, S100A8, S100A6, SMYD2, PRDM9, IGHV1-12, EIF3A, PRKCB, MAPK1, MAP2K1, PSG2, BAALC, PTK7, TBL1XR1, PVT1, EEF1E1, HAVCR2, TOM1, TAM, MUC1, BTLA, PTPRG, STAT1, SSTR4, TES, CASP8AP2, NFKB1, NM, SYBU, NNMT, MAFK, DAZAP1, TPPP2, SOX4, SNX2, NT5E, OPRK1, PAEP, PRKN, WNT3A, PDGFRA, STIL, ZEB2, PECAM1, VPREB1, NAT1, GATA2, EPHA3, ETFA, BRAF, ERBB2, EPO, BMP4, HLA-C, CEACAM5, EPHX1, HLA-DQB1, CEACAM1, CFL1, HMMR, CEACAM3, HOXA5, CCN1, CEACAM8, ENO2, ENG, CHEK1, HOXB7, SERPINC1, HSPB1, ABCC2, EGF, ICAM1, IFNB1, IGF1, IGFBP2, MECOM, EXT1, BRS3, F3, FOLH1, FN1, FUS, G6PD, CCK, CBL, FLT3LG, CBFB, FOXO1, CD28, FGF2, CD80, FAT1, GFI1, CAT, CASP10, FANCC, CAMP, CXCR3, GPR42, GPT, CD58, DDR1, GSK3B, GSTM2, MSH6, BTK, IGFBP3, CEACAM7, FOS, CSF3R, CTLA4, AHR, EDNRA, E2F1, IRS1, CXCL8, DPYD, CTSG, ACTB, DCC, INPP5D, IL4, ADRA2B, ADRA1A, IL6ST, ABO, KIR2DS1, DPP4, TCFL5, DDX41, CD70, CD47, ERVW-1, IL23A, HDAC7, CST3, TRIM33, EMCN, CD72, WWOX, IGF2BP2, ZMYND11, ISYNA1, KDM5B, WNT16, WAC, TMED7, CD69, CD48, CD59, CSN2, MAP3K20, THEG, DCTN6, TNFSF13B, ZBTB7A, PLK4, DACT1, EBP, CD37, BCL11A, IGF2BP3, SEPTIN11, CD2, CD1D, PRDX4, CCND3, ATF7IP, ANP32B, CNDP2, ZNRD2, CCND2, CXCL13, CCNC, CYBB, ACSS2, CIB2, ZC4H2, MYDGF, CYLD, PRMT5, IMPACT, CD5, KDM3B, COLEC10, ARPP21, IL17D, TLR9, H2BS1, RIN2, PDLIM5, CD36, ADAMTSL4, TNFSF8, QRSL1, FBLIM1, GIPC2, WBP1L, TNFRSF8, MOCOS, MSTO1, ELP2, CD14, CD79B, RASSF1, GPR132, CKS1B, COBL, ATP11A, ARHGEF12, CCR5, DICER1, CKS2, SPIDR, CLCF1, CISH, CHI3L1, SSBP2, LY96, PLA2G15, TFIP11, FBXL2, LETMD1, CHRNA4, RIPK3, MLC1, CYFIP1, MPRIP, CNTFR, CREB1, CASC3, WDHD1, CILK1, CARD8, SACM1L, KLRK1, CRHR1, CORO1A, MAPRE1, CR1, CD160, ADAMTS13, USP33, WWP1, PIM2, SEPTIN6, CHRM3, NAT9, CDH11, TRBV7-9, CEL, CEBPA, HCST, CDX2, HPSE, PPP1R13L, CDKN2D, TRBV16, TRBC1, STAP1, TRAC, TRIB2, SETD2, CDK9, POLG2, CD274, CCR9, CDH13, IGHV3-69-1, NMU, IGHV3OR16-7, SMR3B, FBXL5, FBXO8, TSPAN16, CRKL, STEAP1, SLC27A4, CEACAM4, SLC27A5, DKK3, DKK2, PCDHA@, AGO2, NAAA, RAB40B, IL17C, CSF1, PCDH17, NEU3, KIR3DL2, RNF20, AREG, BIRC2, MIR15A, MIR16-1, MIR17, ANXA5, MIR185, MIR187, MIR192, MIR196A1, ANXA2, MIR206, MIR210, MIR181A1, MIR214, MIR22, ALPP, ALPI, MIR29B1, MIR29B2, MIR29C, MIR31, APRT, MIR144, ALK, MIR143, BCRP4, PGP, HOXA-AS2, BCL9, DDX51, CLEC4D, ADAMTSL5, ABCB5, H3P44, TICAM2, BAK1, B2M, ATRX, ATR, ATIC, MIR100, MIR125B1, MIR125B2, MIR128-2, MIR137, ASS1, MIR34A, MIR9-2, PCSK9, CDKN2B-AS1, SYCE1L, MFT2, ADM, ACTN4, TMED7-TICAM2, ACTG1, MIR3117, MIR2909, SNHG16, PPR1, KLRC4-KLRK1, COMMD3-BMI1, LOC102723407, LOC102724334, CBSL, LOC102724971, MTCO2P12, ABCA3, H3P13, H3P23, H3P47, MIR665, GGTLC4P, MIR9-3, GGT2, MIR99A, MIR17HG, BLID, AKR1B1, ALB, MIR339, AFM, MIR424, MIR425, H4C15, MIR499A, POU5F1P3, ADRB2, POU5F1P4, GGTLC5P, SNORD116@, MIR595, MIR625, MIR652, GGTLC3, POTEF, GCSAM, ZDHHC23, METTL3, SLC28A3, TNMD, CBFA2T3, FBRS, IKZF5, GORASP1, PLEKHG2, RANBP17, BCL11B, RUNX2, WNK1, CAV3, ZMAT4, CASP2, CAPG, TRABD, PNPLA3, TSGA10, PBX4, LBH, AMN, DOCK8, ELSPBP1, PRDM16, MXD3, HPSE2, FMN2, SPHK2, TCIM, CBS, SLC12A9, CBLB, KNL1, AVEN, ZNF695, GOPC, SALL4, RUNX3, SCYL1, BIRC6, DLEU1, PCDH10, KLHL1, METTL14, CCAR2, KMT2C, BACH2, CALR, CALCR, CERS6, EXOSC6, BRCA1, BMP6, UHMK1, SLX4IP, CMPK2, BLVRB, PRRC1, PACRG, CTCFL, CXCR5, PDIK1L, BHMT, CREBRF, CLEC12A, ZNF296, RASSF6, CFB, DLEU7, ZEB1-AS1, JMJD1C, IL27, H4-16, TWIST2, CHST9, TADA1, AIF1L, PARP9, SETDB2, MAGT1, BUB1, ZCCHC7, MAML2, ACCS, ATAD1, ZNF382, UBASH3B, ABCC11, ZFP36L2, LHX4, RCSD1, DNER, UBE2Q2, PRRT2, NLRP3, FCRL1, ZFP36L1, CYP1B1, DNMT1, LILRB2, PMAIP1, PNN, SEPTIN5, SEPTIN4, POLD1, POMC, POU5F1, PPARA, PTPA, PRF1, HIF1A, HIC1, HDC, HDAC2, PRKCA, HAL, H2AZ1, GZMB, MAPK8, GZMA, MAP2K2, MAP2K7, HK1, PLK1, CYP2C19, PLCG2, HOXB5, HOXB4, PAM, HOXB3, PARN, HOXB2, HOXB1, PCNA, PDE1A, PDGFB, HOXB@, HOXA10, SLC29A2, HNF4A, HMOX1, HMGB1, HLX, PIM1, HLA-DRA, HLA-DQA1, PLAT, EIF2AK2, PRPS1, PRSS1, GYPE, RPL22, GLI3, GLI2, GH1, S100A9, S100A10, GGT1, SCD, SRL, CCL2, CCL3, CCL4, CCL21, CCL22, XCL1, GFER, SELE, SELPLG, GDF10, SRSF2, SFTPD, BRD2, RMRP, RIT1, PVR, GYPB, PSMD9, PSMD12, GYPA, PTGS2, GSTM3, GRIK2, GRIA1, PTPRO, RAG2, GML, RAP1GDS1, GPER1, PLAAT4, KDM5A, RBBP4, GNG11, REG1A, GNA15, REN, P4HB, OTC, SIX6, MAP3K10, LYL1, LYN, MARCKS, SMAD7, MAOA, MAPT, MBL2, MBP, IRF3, MCM2, CD46, SMCP, IRF1, INSR, MEF2C, CXCL10, MEFV, ING2, MFAP1, KITLG, IL16, CYP4F3, LTB, LTA, LEPR, KIR2DL1, KCNH2, CD82, JUND, STMN1, LBR, JUNB, LCN2, JUN, LGALS1, LSS, LGALS3, ITPR1, LIPA, FADS1, ITGB1, ITGAM, ITGA4, LPL, IRF4, IL12B, IL12A, OPRM1, IL11, NELL1, NFATC2, NFIL3, NFKB2, NGFR, NKX3-1, HSPA5, HSPA4, PRMT1, NOS3, HRAS, NOTCH2, HPR, PNP, HOXD4, HOXB9, YBX1, HOXB8, NTRK1, NUP88, HOXB6, NEDD9, NEDD8, HSPB2, IGL, MMP1, IL1RN, MOS, CD200, MPL, IL1A, MPP1, MPST, MRE11, RBPJ, IAPP, MSR1, IGFBP4, COX2, MTHFD1, IGFBP1, IGF2, IFI27, MYH11, CEACAM6, KAT2A, SIAH2, GATA4, HSPB3, ELK3, AKR1C3, SOCS1, ELK1, BECN1, ELF3, TNFSF13, ELANE, FADD, TRIM24, EIF5A, EGR1, EGFR, CFLAR, HDAC3, NR1I2, PER3, SQSTM1, EFNB1, ENDOU, BCL10, PIK3R3, IRS4, ELN, GFI1B, EPHA1, KMT2D, HMGA2, TCL1A, TAF15, COIL, MLRL, H4C9, CTTN, H4C1, H4C14, H4C4, H4C6, H4C12, H4C11, H4C3, H4C8, H4C2, H4C5, H4C13, MBD2, NOL3, EPHB2, PHC1, DNM2, SARDH, DLX3, HDAC6, HDAC5, TIMM8A, DEFB1, DHX15, ABCC5, ABCB6, PPIF, RASGRP1, DDC, NAMPT, BRINP1, DAP, TRIB1, MSLN, SPRY1, CD55, NET1, P2RY14, DNMT3A, HDAC4, CD83, PKD2L1, SPAG9, PIAS2, ARHGEF1, EDNRB, IL1RL1, AURKB, MSC, PDLIM7, KLF4, KMT2B, SLIT2, NRXN1, DUSP7, PIGL, BAG4, CLOCK, NCOR1, TCL1B, DNTT, KAT6A, EPHB4, SLA, THY1, FLT4, TACR1, FLII, TAT, TCF4, FLI1, TCF7, ZEB1, TCF12, TCOF1, TRB, FOXM1, FH, FER, TERC, TERF1, FDXR, TFR2, FCGRT, FCGR2B, THBD, SYT1, AFF2, ABCC8, GAD1, SLC6A8, GAS6, SLC25A1, SLCO1A2, SMARCA1, SMARCB1, GART, FSCN1, GAPDH, SOD2, AURKA, SORL1, SOS1, SOX11, SPI1, FRAXE, SST, FOSB, STAT3, STC1, THPO, TIMP2, DEK, TLE1, F2R, VEGFC, VIS1, TRPV1, EWSR1, LAT2, ETS1, WNT7A, WNT10B, WNT2B, ESR1, ERCC1, XRCC1, XRCC3, XRCC5, ZBTB16, ZBTB17, MAP3K12, PRDM2, MOGS, USP7, VCP, NR1H2, UNG, TTC4, FAP, TMSB4X, PTK2B, TNFRSF1A, TOP2A, FABP3, TPM3, F10, NR2C2, TNFSF4, UCK2, TNFRSF4, TXN, TYK2, F9, TYRO3, F8, UCHL1, UCN, UMOD, RELA

Drugs

(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol, 6-thioguanine (oral liquid), Allogeneic CD34+ cells expanded ex vivo with an aryl hydrocarbon receptor antagonist, Allogeneic T cells encoding an exogenous TK gene, Allogeneic ex vivo expanded umbilical cord blood cells, Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2, Aplidine, Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor), Autologous engineered anti -CD19 Chimeric Antigen Receptor (CAR +) T -cells ( KYMRIAH ), Axicabtagene ciloleucel ( YESCARTA ), Blinatumomab ( BLINCYTO ), Clofarabine ( CLOLAR, EVOLTRA, IVOZALL ), Crisantaspase, Dasatinib ( SPRYCEL ), Epratuzumab, Eryaspase ( GRASPA ), Forodesine hydrochloride, Hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor (AHR) antagonist, Imatinib mesilate ( GLEEVEC, GLIVEC, IMATINIB TEVA, IMATINIB TEVA B.V. ), Inotuzumab ozogamicin ( BESPONSA ), Iodine (131I) tositumomab, L-Asparaginase ( KIDROLASE, SPECTRILA ), Mercaptopurine (oral liquid), Mercaptopurine (oral suspension) ( PURIXAN, XALUPRINE ), Methotrexate (oral liquid) ( JYLAMVO ), Moxetumomab pasudotox ( LUMOXITI ), Nelarabine ( ARRANON, ATRIANCE ), Pegaspargase ( ONCASPAR, PEGASPAR ), Pegylated L-asparaginase, Pegylated recombinant Erwinia chrysanthemi L-asparaginase, Plitidepsin, Ponatinib ( ICLUSIG ), Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3, Siplizumab, Stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells, Vincristine sulfate liposomes ( MARQIBO ), haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate

Interested in hearing about new therapies?

Overview

Acute lymphocytic leukemia (ALL) is a type of cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made.

The word "acute" in acute lymphocytic leukemia comes from the fact that the disease progresses rapidly and creates immature blood cells, rather than mature ones. The word "lymphocytic" in acute lymphocytic leukemia refers to the white blood cells called lymphocytes, which ALL affects. Acute lymphocytic leukemia is also known as acute lymphoblastic leukemia.

Acute lymphocytic leukemia is the most common type of cancer in children, and treatments result in a good chance for a cure. Acute lymphocytic leukemia can also occur in adults, though the chance of a cure is greatly reduced.

Symptoms

Signs and symptoms of acute lymphocytic leukemia may include:

Bleeding from the gums
Bone pain
Fever
Frequent infections
Frequent or severe nosebleeds
Lumps caused by swollen lymph nodes in and around the neck, armpits, abdomen or groin
Pale skin
Shortness of breath
Weakness, fatigue or a general decrease in energy

When to see a doctor

Make an appointment with your doctor or your child's doctor if you notice any persistent signs and symptoms that concern you.

Many signs and symptoms of acute lymphocytic leukemia mimic those of the flu. However, flu signs and symptoms eventually improve. If signs and symptoms don't improve as expected, make an appointment with your doctor.

Causes

Acute lymphocytic leukemia occurs when a bone marrow cell develops changes (mutations) in its genetic material or DNA. A cell's DNA contains the instructions that tell a cell what to do. Normally, the DNA tells the cell to grow at a set rate and to die at a set time. In acute lymphocytic leukemia, the mutations tell the bone marrow cell to continue growing and dividing.

When this happens, blood cell production becomes out of control. The bone marrow produces immature cells that develop into leukemic white blood cells called lymphoblasts. These abnormal cells are unable to function properly, and they can build up and crowd out healthy cells.

It's not clear what causes the DNA mutations that can lead to acute lymphocytic leukemia.

Risk factors

Factors that may increase the risk of acute lymphocytic leukemia include:

Previous cancer treatment. Children and adults who've had certain types of chemotherapy and radiation therapy for other kinds of cancer may have an increased risk of developing acute lymphocytic leukemia.
Exposure to radiation. People exposed to very high levels of radiation, such as survivors of a nuclear reactor accident, have an increased risk of developing acute lymphocytic leukemia.
Genetic disorders. Certain genetic disorders, such as Down syndrome, are associated with an increased risk of acute lymphocytic leukemia.

Diagnosis

Tests and procedures used to diagnose acute lymphocytic leukemia include:

Blood tests. Blood tests may reveal too many or too few white blood cells, not enough red blood cells, and not enough platelets. A blood test may also show the presence of blast cells — immature cells normally found in the bone marrow.
Bone marrow test. During bone marrow aspiration and biopsy, a needle is used to remove a sample of bone marrow from the hipbone or breastbone. The sample is sent to a lab for testing to look for leukemia cells.

Doctors in the lab will classify blood cells into specific types based on their size, shape, and other genetic or molecular features. They also look for certain changes in the cancer cells and determine whether the leukemia cells began from B lymphocytes or T lymphocytes. This information helps your doctor develop a treatment plan.
Imaging tests. Imaging tests such as an X-ray, a computerized tomography (CT) scan or an ultrasound scan may help determine whether cancer has spread to the brain and spinal cord or other parts of the body.
Spinal fluid test. A lumbar puncture test, also called a spinal tap, may be used to collect a sample of spinal fluid — the fluid that surrounds the brain and spinal cord. The sample is tested to see whether cancer cells have spread to the spinal fluid.

Determining your prognosis

Your doctor uses information gathered from these tests and procedures to determine your prognosis and decide on your treatment options. Other types of cancer use numerical stages to indicate how far the cancer has spread, but there are no stages of acute lymphocytic leukemia.

Instead, the seriousness of your condition is determined by:

The type of lymphocytes involved — B cells or T cells
The specific genetic changes present in your leukemia cells
Your age
Results from lab tests, such as the number of white blood cells detected in a blood sample

Treatment

In general, treatment for acute lymphocytic leukemia falls into separate phases:

Induction therapy. The purpose of the first phase of treatment is to kill most of the leukemia cells in the blood and bone marrow and to restore normal blood cell production.
Consolidation therapy. Also called post-remission therapy, this phase of treatment is aimed at destroying any remaining leukemia in the body.
Maintenance therapy. The third phase of treatment prevents leukemia cells from regrowing. The treatments used in this stage are usually given at much lower doses over a long period of time, often years.
Preventive treatment to the spinal cord. During each phase of therapy, people with acute lymphocytic leukemia may receive additional treatment to kill leukemia cells located in the central nervous system. In this type of treatment, chemotherapy drugs are often injected directly into the fluid that covers the spinal cord.

Depending on your situation, the phases of treatment for acute lymphocytic leukemia can span two to three years.

Treatments may include:

Chemotherapy. Chemotherapy, which uses drugs to kill cancer cells, is typically used as an induction therapy for children and adults with acute lymphocytic leukemia. Chemotherapy drugs can also be used in the consolidation and maintenance phases.
Targeted therapy. Targeted drug treatments focus on specific abnormalities present within cancer cells. By blocking these abnormalities, targeted drug treatments can cause cancer cells to die. Your leukemia cells will be tested to see if targeted therapy may be helpful for you. Targeted therapy can be used alone or in combination with chemotherapy for induction therapy, consolidation therapy or maintenance therapy.
Radiation therapy. Radiation therapy uses high-powered beams, such as X-rays or protons, to kill cancer cells. If the cancer cells have spread to the central nervous system, your doctor may recommend radiation therapy.
Bone marrow transplant. A bone marrow transplant, also known as a stem cell transplant, may be used as consolidation therapy or for treating relapse if it occurs. This procedure allows someone with leukemia to reestablish healthy bone marrow by replacing leukemic bone marrow with leukemia-free marrow from a healthy person.

A bone marrow transplant begins with high doses of chemotherapy or radiation to destroy any leukemia-producing bone marrow. The marrow is then replaced by bone marrow from a compatible donor (allogeneic transplant).
Engineering immune cells to fight leukemia. A specialized treatment called chimeric antigen receptor (CAR)-T cell therapy takes your body's germ-fighting T cells, engineers them to fight cancer and infuses them back into your body.

CAR-T cell therapy might be an option for children and young adults. It might be used for consolidation therapy or for treating relapse.
Clinical trials. Clinical trials are experiments to test new cancer treatments and new ways of using existing treatments. While clinical trials give you or your child a chance to try the latest cancer treatment, the benefits and risks of the treatment may be uncertain. Discuss the benefits and risks of clinical trials with your doctor.

Treatment for older adults

Older adults, such as those older than 65, tend to experience more complications from treatments. And older adults generally have a worse prognosis than children who are treated for acute lymphocytic leukemia.

Discuss your options with your doctor. Based on your overall health and your goals and preferences, you may decide to undergo treatment for your leukemia.

Some people may choose to forgo treatment for the cancer, instead focusing on treatments that improve their symptoms and help them make the most of the time they have remaining.

Clinical trials

Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this condition.

Alternative medicine

No alternative treatments have been proved to cure acute lymphocytic leukemia. But some alternative therapies may help ease the side effects of cancer treatment and make you or your child more comfortable. Discuss your options with your doctor, as some alternative treatments could interfere with cancer treatments, such as chemotherapy.

Alternative treatments that may ease symptoms include:

Acupuncture
Exercise
Massage
Meditation
Relaxation activities, including yoga and tai chi

Coping and support

Treatment for acute lymphocytic leukemia can be a long road. Treatment often lasts two to three years, although the first months are the most intense.

During maintenance phases, children can usually live a relatively normal life and go back to school. And adults may be able to continue working. To help you cope, try to:

Learn enough about leukemia to feel comfortable making treatment decisions. Ask your doctor to write down as much information about your specific disease as possible. Then narrow your search for information accordingly.

Write down questions you want to ask your doctor before each appointment, and look for information in your local library and on the internet. Good sources include the National Cancer Institute, the American Cancer Society, and the Leukemia & Lymphoma Society.
Lean on your whole health care team. At major medical centers and pediatric cancer centers, your health care team may include psychologists, psychiatrists, recreation therapists, child-life workers, teachers, dietitians, chaplains and social workers. These professionals can help with a whole host of issues, including explaining procedures to children, finding financial assistance and arranging for housing during treatment. Don't hesitate to rely on their expertise.
Explore programs for children with cancer. Major medical centers and nonprofit groups offer numerous activities and services specifically for children with cancer and their families. Examples include summer camps, support groups for siblings and wish-granting programs. Ask your health care team about programs in your area.
Help family and friends understand your situation. Set up a free, personalized webpage at the nonprofit website CaringBridge. This allows you to tell the whole family about appointments, treatments, setbacks and reasons to celebrate — without the stress of calling everyone every time there's something new to report.

Preparing for your appointment

Make an appointment with your family doctor if you or your child has signs and symptoms that worry you. If your doctor suspects acute lymphocytic leukemia, you'll likely be referred to a doctor who specializes in treating diseases and conditions of the blood and bone marrow (hematologist).

Because appointments can be brief, and because there's often a lot of information to discuss, it's a good idea to be prepared. Here's some information to help you get ready, and what to expect from the doctor.

What you can do

Be aware of any pre-appointment restrictions. At the time you make the appointment, be sure to ask if there's anything you need to do in advance, such as restrict your diet.
Write down any symptoms you're experiencing, including any that may seem unrelated to the reason for which you scheduled the appointment.
Write down key personal information, including any major stresses or recent life changes.
Make a list of all medications, vitamins or supplements that you're taking.
Consider taking a family member or friend along. Sometimes it can be difficult to remember all the information provided during an appointment. Someone who accompanies you may remember something that you missed or forgot.
Write down questions to ask your doctor.

Your time with your doctor is limited, so preparing a list of questions can help you make the most of your time together. List your questions from most important to least important in case time runs out. For acute lymphocytic leukemia, some basic questions to ask the doctor include:

What is likely causing these symptoms?
What are other possible causes for these symptoms?
What kinds of tests are necessary?
Is this condition likely temporary or chronic?
What is the best course of action?
What are the alternatives to the primary approach that you're suggesting?
How can other existing health conditions be best managed with ALL?
Are there any restrictions that need to be followed?
Is it necessary to see a specialist? What will that cost, and will my insurance cover it?
Is there a generic alternative to the medicine you're prescribing me?
Are there brochures or other printed material that I can take with me? What websites do you recommend?
What will determine whether I should plan for a follow-up visit?

In addition to the questions that you've prepared to ask your doctor, don't hesitate to ask other questions.

What to expect from the doctor

The doctor is likely to ask you a number of questions. Being ready to answer them may allow time to cover other points you want to address. Your doctor may ask:

When did symptoms begin?
Have these symptoms been continuous or occasional?
How severe are these symptoms?
What, if anything, seems to improve these symptoms?
What, if anything, appears to worsen these symptoms?

What you can do in the meantime

Avoid activity that seems to worsen any signs and symptoms. For instance, if you or your child is feeling fatigued, allow for more rest. Determine which of the day's activities are most important, and focus on accomplishing those tasks.